FDA Grants AP Status for Amantadine Hydrochloride ANDA210215
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Amantadine Hydrochloride submitted by POM Pharma.
Company
Pharmaceutical intelligence for POM Pharma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.